Eisai/Biogen’s Lecanemab Faces Smoother Passage Through US FDA Than Aducanumb

 
• By Sue Sutter
  
Smooth sailing
The regulatory sailing should be smoother for Eisai/Biogen's second-in-class amyloid-targeted antibody lecanemab. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Product Reviews

More from Pink Sheet